Re: Efficacy of methylcobalamin and folinic acid treatment on glutathione redox stat

[Guest guest]

----- Original Message -----

From: sammysouthie

===>Last paragraph: Note the use of the words " useful in SOME children " .

Contrary to the dan! position that ALL children should have mb12 shots. Mb12 has

been a detrimental for some children also, was for ours.

1: Am J Clin Nutr. 2008 Dec 3. [Epub ahead of print]Efficacy of

methylcobalamin and folinic acid treatment on glutathione redox

status in children with autism. SJ, Melnyk S, Fuchs G, Reid T,

Jernigan S, Pavliv O, Hubanks A, Gaylor DW.

Departments of Pediatrics and Biostatistics, University of Arkansas

for Medical Sciences, Arkansas Children's Hospital Research

Institute, Little Rock, AR.

BACKGROUND: Metabolic abnormalities and targeted treatment trials

have been reported for several neurobehavioral disorders but are

relatively understudied in autism. OBJECTIVE: The objective of this

study was to determine whether or not treatment with the metabolic

precursors, methylcobalamin and folinic acid, would improve plasma

concentrations of transmethylation/transsulfuration metabolites and

glutathione redox status in autistic children. DESIGN: In an open-

label trial, 40 autistic children were treated with 75 mug/kg

methylcobalamin (2 times/wk) and 400 mug folinic acid (2 times/d) for

3 mo. Metabolites in the transmethylation/transsulfuration pathway

were measured before and after treatment and compared with values

measured in age-matched control children. RESULTS: The results

indicated that pretreatment metabolite concentrations in autistic

children were significantly different from values in the control

children. The 3-mo intervention resulted in significant increases in

cysteine, cysteinylglycine, and glutathione concentrations (P <

0.001). The oxidized disulfide form of glutathione was decreased and

the glutathione redox ratio increased after treatment (P < 0.008).

Although mean metabolite concentrations were improved significantly

after intervention, they remained below those in unaffected control

children. CONCLUSIONS: The significant improvements observed in

transmethylation metabolites and glutathione redox status after

treatment suggest that targeted nutritional intervention with

methylcobalamin and folinic acid may be of clinical benefit in some

children who have autism. This trial was registered at

clinicaltrials.gov as NCT00692315.

PMID: 19056591 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/19056591?

ordinalpos=4 & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pu

bmed_DefaultReportPanel.Pubmed_RVDocSum

[Guest guest]

--- Yes......probably useful in those who do not process folic

acidand those who's methionine synthase is not correctly working. As

we know folate given when b-12 status is inadequate causes cognitive

decline.....We also know methyl b-12 is neuro protective to some

degree.My major point is that the mainstream is slowly catching up to

the science we already know.....[these kids were poisoned]As they do

they are validating what we akready know..... Your study of one[your

child] my study of one[my child]and all the other parent studies of[

thier child] Is equally important and very relevant to this debate.

Personally , The methyl b-12 provided neuro protection for my child

when a complete idiot gave him nitros oxide [after me telling him not

to] creating a b-12 anemia. In Autism-

Mercury , " " <Ladyshrink111@...> wrote:

>

>

> ----- Original Message -----

> From: sammysouthie

>

> ===>Last paragraph: Note the use of the words " useful in SOME

children " . Contrary to the dan! position that ALL children should

have mb12 shots. Mb12 has been a detrimental for some children also,

was for ours.

>

>

>

>

> 1: Am J Clin Nutr. 2008 Dec 3. [Epub ahead of print]Efficacy of

> methylcobalamin and folinic acid treatment on glutathione redox

> status in children with autism. SJ, Melnyk S, Fuchs G, Reid

T,

> Jernigan S, Pavliv O, Hubanks A, Gaylor DW.

> Departments of Pediatrics and Biostatistics, University of

Arkansas

> for Medical Sciences, Arkansas Children's Hospital Research

> Institute, Little Rock, AR.

>

> BACKGROUND: Metabolic abnormalities and targeted treatment trials

> have been reported for several neurobehavioral disorders but are

> relatively understudied in autism. OBJECTIVE: The objective of

this

> study was to determine whether or not treatment with the

metabolic

> precursors, methylcobalamin and folinic acid, would improve

plasma

> concentrations of transmethylation/transsulfuration metabolites

and

> glutathione redox status in autistic children. DESIGN: In an open-

> label trial, 40 autistic children were treated with 75 mug/kg

> methylcobalamin (2 times/wk) and 400 mug folinic acid (2 times/d)

for

> 3 mo. Metabolites in the transmethylation/transsulfuration

pathway

> were measured before and after treatment and compared with values

> measured in age-matched control children. RESULTS: The results

> indicated that pretreatment metabolite concentrations in autistic

> children were significantly different from values in the control

> children. The 3-mo intervention resulted in significant increases

in

> cysteine, cysteinylglycine, and glutathione concentrations (P <

> 0.001). The oxidized disulfide form of glutathione was decreased

and

> the glutathione redox ratio increased after treatment (P <

0.008).

> Although mean metabolite concentrations were improved

significantly

> after intervention, they remained below those in unaffected

control

> children. CONCLUSIONS: The significant improvements observed in

> transmethylation metabolites and glutathione redox status after

> treatment suggest that targeted nutritional intervention with

> methylcobalamin and folinic acid may be of clinical benefit in

some

> children who have autism. This trial was registered at

> clinicaltrials.gov as NCT00692315.

>

> PMID: 19056591 [PubMed - as supplied by publisher]

>

> http://www.ncbi.nlm.nih.gov/pubmed/19056591?

>

ordinalpos=4 & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pu

> bmed_DefaultReportPanel.Pubmed_RVDocSum

>

>

>

>

>

>